摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-amino-1-(β-D-ribofuranosyl)imidazole-4-(N-benzyl)carboxamide | 20735-74-4

中文名称
——
中文别名
——
英文名称
5-amino-1-(β-D-ribofuranosyl)imidazole-4-(N-benzyl)carboxamide
英文别名
5-amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxylic acid benzylamide;5-Amino-1-β-D-ribofuranosyl-1H-imidazol-4-carbonsaeure-benzylamid;5-amino-1-β-D-riboruranosylimidazole-4-N-(benzyl)carboxamide;5-amino-N-benzyl-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxamide
5-amino-1-(β-D-ribofuranosyl)imidazole-4-(N-benzyl)carboxamide化学式
CAS
20735-74-4
化学式
C16H20N4O5
mdl
——
分子量
348.359
InChiKey
QEOKLNZVPLJMJR-XNIJJKJLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    170-173 °C
  • 沸点:
    791.7±60.0 °C(Predicted)
  • 密度:
    1.60±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    143
  • 氢给体数:
    5
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    5-Amino-4-imidazolecarboxamide Riboside from Inosine. Ring-opening Reactions of Purine Nucleosides
    摘要:
    DOI:
    10.1021/ja01548a025
  • 作为产物:
    描述:
    N1-benzylinosinesodium hydroxide 作用下, 以68%的产率得到5-amino-1-(β-D-ribofuranosyl)imidazole-4-(N-benzyl)carboxamide
    参考文献:
    名称:
    从肌苷轻松合成 AICAR
    摘要:
    5-Amino-1-β-D-ribofuranosylimidazole-4-carboxamide (AICAR; 1)(图 I)是由肌苷通过其 1-烷氧基甲基衍生物有效制备的。这些衍生物的稳定性使其能够通过柱色谱法(硅胶)进行纯化。该操作确保了1的高质量,通过衍生物的碱解以良好的收率获得了1。
    DOI:
    10.1055/s-2003-42455
点击查看最新优质反应信息

文献信息

  • METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
    申请人:Stover Richard R.
    公开号:US20080175891A1
    公开(公告)日:2008-07-24
    The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.
    本发明提供了通过经皮途径给予AICA核糖苷,或其前药、类似物或盐,和/或血液凝块抑制剂以预防或减少患者的不良副作用。可能受益的患者类型包括左心室功能减退的患者、先前发生心肌梗死的患者、接受非血管手术的患者,或分娩期间的胎儿。
  • Conformational restraint is a critical determinant of unnatural nucleotide recognition by protein kinases
    作者:Scott M Ulrich、Nathan A Sallee、Kevan M Shokat
    DOI:10.1016/s0960-894x(02)00616-9
    日期:2002.11
    This report describes the synthesis of N-4-(benzyl) AICAR triphosphate, a conformationally restrained analogue of N-4-(benzyl) ribavirin triphosphate. Both of these nucleotides were evaluated as phosphodonors for wild-type p38 MAP kinase and T106G p38MAP kinase, a designed mutant with expanded nucleotide specificity. The conformationally restrained nucleotide, N-4-(benzyl) AICAR triphosphate, is orthogonal to (not accepted as a substrate by) wild-type p38MAP kinase, in contrast to N-4-(benzyl) ribavirin triphosphate. Furthermore, N-4-(benzyl) AICAR triphosphate, is accepted as a substrate by T106G p38 MAP kinase, in contrast to N-4-(benzyl) ribavirin triphosphate. We hypothesize that the presence of an internal hydrogen bond in N-4-(benzyl) AICAR and its absence in N-4-(benzyl) ribavirin triphosphate is the main determinant for their differing structure-activity relationships. (C) 2002 Elsevier Science Ltd. All rights reserved.
  • Synthesis of 4-N-alkyl and ribose-modified AICAR analogues on solid support
    作者:Giorgia Oliviero、Jussara Amato、Nicola Borbone、Stefano D'Errico、Gennaro Piccialli、Enrico Bucci、Vincenzo Piccialli、Luciano Mayol
    DOI:10.1016/j.tet.2008.04.071
    日期:2008.6
    Herein, we report the solid-phase synthesis of several 5-aminoimidazole-4-(N-alkyl)carboxamide-1-ribosides (4-N-alkyl AICARs) and the corresponding 2',3'-secoriboside derivatives. The method uses the N-1-dinitrophenyl-inosine 5'-bonded to a solid support. This inosine derivative has the C-2 of the purine base strongly activated towards the attack of N-nucleophiles thus allowing the preparation of several N-1 alkylated inosine supports from which a small library of 4-N-alkyl AICAR derivatives has been synthesized. A set of new 4-N-alkyl AICA-2',3'-secoriboside derivatives have also been obtained in high yields by solid-phase cleavage of the 2',3'-ribose bond. (c) 2008 Elsevier Ltd. All rights reserved.
  • WO2006/105167
    申请人:——
    公开号:——
    公开(公告)日:——
  • 5-Amino-4-imidazolecarboxamide Riboside from Inosine. Ring-opening Reactions of Purine Nucleosides
    作者:Elliott Shaw
    DOI:10.1021/ja01548a025
    日期:1958.8
查看更多

同类化合物

阿卡地新 咪唑立宾 5'-单磷酸酯 咪唑立宾 [(2R,3S,4R,5R)-5-[4-氨基甲酰-5-[[(3R,4R)-3,4-二羟基-2-氧代-5-膦酰氧基戊基]亚氨基甲基氨基]咪唑-1-基]-3,4-二羟基四氢呋喃-2-基]磷酸二氢甲酯 N-[5-氨基-1-(BETA-D-呋喃核糖基)咪唑-4-羰基]-L-天冬氨酸 5-碘-1-(2’,3’,5’-三-O-乙酰基-beta-D-呋喃核糖基)-咪唑并-4-甲腈 5-甲酰氨基咪唑-4-甲酰胺核苷酸 5-氯-1-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]咪唑-4-甲酰胺 5-氨基-4-咪唑甲酰胺核糖甙 5'-三磷酸酯 5-氨基-1-(2-O,3-O,5-O-三乙酰基-beta-D-呋喃核糖基)-1H-咪唑-4-甲酰胺 5-氨基-1-(2,7-二羟基-2-氧代四氢-4H-呋喃并[3,2-d][1,3,2]二氧杂环己膦烷-6-基)-1H-咪唑-4-甲酰胺 5-乙炔基-1-呋喃核糖基咪唑-4-甲酰胺 4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑 2-硝基-1-beta-D-呋喃核糖基-1H-咪唑 1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑 1-(alpha-D-阿拉伯呋喃糖基)-1H-咪唑-2-胺 (2S)-2-[[5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-(膦酰氧基甲基)四氢呋喃-2-基]咪唑-4-羰基]氨基]丁二酸 (2R)-2-环己基-2-羟基-2-苯基乙酸 (1-羟基乙基)-5-甲基-1-beta-呋喃核糖基咪唑 5-amino-1-(β-D-ribofuranosyl)-4-(5-propyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-phenyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-ethyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-[1-(Dimethylamino)ethylideneamino]-1-[2,3-O-(1-methylethylidene)-β-D-ribofuranosyl]-imidazole-4-carbonitrile 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-4-(3-ureidophenyl)imidazole 5-amino-2-(4-fluorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(3-chlorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(4-methoxyphenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-phenylvinyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-phenyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-furyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-2-(2-thienyl)-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamideoxime hydrochloride acadesine-5’-O-bis(benzoxy-L-alaninyl)phosphate 5-diazonium-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide 5-amino-1-(3-O-methyl-β-D-ribofuranosyl)imidazole-4-carboxamide 5-amino-1-(3-O-n-butyl-β-D-ribofuranosyl) imidazole-4-carboxamide 5-amino-1-(3-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide 5-amino-1-(2-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide N4-(benzyl) AICAR triphosphate N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleotide N1-<(5''-Phospho-β-D-ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside 2-Benzyl-1-(β-D-ribofuranosyl)imidazol-4,5-dicarboxamid 4-N-[(S)-pyrrolidine-2-carbonyl]amino-1-β-D-ribofuranosylimidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-pentyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-heptyl-1,2,4-oxadiazol-3-yl)imidazole acadesine-5’-O-bis(methoxy-L-alaninyl)phosphate 4,5-dichloro-1-(β-D-ribofuranosyl)imidazole